OncBioMune Phase 2 Prostate Cancer Trial in Mexico Key to Expedited Commercialization

OncBioMune Pharmaceuticals (OTCMKTS:OBMP) announced the partnership with Vitel Laboratorios in Mexico could be a valuable shortcut towards seeing if its prostate cancer vaccine can be commercialized in an abbreviated fashion.
As quoted in the press release:

Vitel has a well-established presence in the Mexican pharmaceutical space and overseas ties and has used their experience to move quickly with signing principal investigators for a Phase 2 trial and set up key meetings with regulatory authorities, similar to the FDA process in the U.S.  For the protocol, OncBioMune was able to leverage an ongoing Phase 1 trial in California evaluating ProscaVax in recurrent prostate cancer patients and preparatory work being done for a separate Phase 2 trial planned to be hosted at Beth Israel Deaconess Medical Center and its hospital network on early-stage prostate cancer patients.
The principal investigators for the Phase 2 Mexican trial, which will evaluate ProscaVax in PSA recurrent prostate cancer in hormone-naïve and hormone-independent patients, have green lighted the protocol with the final document expected to be submitted to IMSS, the national public health care system in Mexico, in the next few weeks.
The company says that it is receiving tremendous support from Mexican officials with respect to developing ProscaVax, which dovetails with prior statements about potentially hastening the commercialization process if the trial produces positive outcomes.  Manuel Cosme Odabachian, CEO of Vitel, has stated that Mexico is aiming to become a global leader in drug development, something that it has typically trailed the world in doing.  Prostate cancer, the most frequently diagnosed cancer in men of 50 in the country, is a growing concern in Mexico with its aging population and more than 300,000 new diagnoses each year.

OncBioMune Pharmaceuticals President and CFO, Andrew Kucharchuk, stated:

Everything is, of course, contingent on the clinical data, but what we’ve seen so far in human studies of our vaccines has us very optimistic. As professionals, we always must temper expectations and remain sanguine about trial data until it arrives, but this could be a tremendous catalyst for us and we’re thrilled with the opportunity.

Connect with OncBioMune Pharmaceuticals (OTCMKTS:OBMP) to receive an Investor Presentation.